IMC Chicago
ABVX

IMC Chicago’s Abivax ABVX Stock Holding History

IMC Chicago’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.5M Buy
206,500
+131,900
+177% +$14.9M 0.01% 892
2026
Q1 		$8.31M Buy
74,600
+61,100
+453% +$7.23M ﹤0.01% 1419
2025
Q4 		$1.82M Buy
+13,500
New +$1.47M ﹤0.01% 2507

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IMC Chicago's ABVX Position: Q2 2026 in Review

IMC Chicago reduced its Abivax (ABVX) stake by 18% in Q2 2026, selling an estimated $2.12M and leaving 87,392 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1438.

IMC Chicago first reported a position in ABVX in Q4 2025 and has held it in 3 quarters since. The position peaked at $11.8M in Q1 2026. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • IMC Chicago held 87,392 shares of Abivax worth $11.6M as of Q2 2026.
  • IMC Chicago sold 18,751 Abivax shares in Q2 2026, an estimated $2.12M.
  • Abivax made up ﹤0.01% of IMC Chicago's portfolio in Q2 2026, its #1438 holding.
  • IMC Chicago first reported a position in Abivax in Q4 2025 and has held it in 3 quarters since.
  • IMC Chicago's Abivax position peaked at $11.8M in Q1 2026.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.